S194: INTEGRATIVE CLINICAL PROTEOTYPING AND DRUG RESPONSE PROFILING IDENTIFIES TARGETABLE BIOLOGY UNDERLYING MYELOPROLIFERATIVE NEOPLASMS
Main Authors: | M. H. Wildschut, M. van Oostrum, J. Settelmeier, J. Mena, C. Dördelmann, Y. Festl, A. Ring, R. C. Skoda, M. Lopes, B. Wollscheid, B. Snijder, A. Theocharides |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843668.08766.86 |
Similar Items
-
Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms
by: Dongdong Huang, et al.
Published: (2022-07-01) -
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis
by: Mattheus H. E. Wildschut, et al.
Published: (2023-10-01) -
Enzymatic Dissociation Induces Transcriptional and Proteotype Bias in Brain Cell Populations
by: Daniele Mattei, et al.
Published: (2020-10-01) -
Myeloproliferative neoplasms
by: Jean-Jacques Kiladjian
Published: (2018-06-01) -
Myeloproliferative neoplasms
by: Nick Cross, (Coordinating Author)
Published: (2019-06-01)